Флебодиа 600 is intended to provide symptomatic relief for conditions falling into two main therapeutic areas. The primary application is addressing functional signs associated with chronic venous and lymphatic insufficiency. This includes common daily discomforts such as heavy legs, pain, and a feeling of leg fatigue, particularly after extended periods of standing. Clinical use suggests that the medication may support functional improvement and contribute to increased comfort in these scenarios.

A secondary use is in the management of acute hemorrhoidal symptoms. In this context, the medicine is known to address functional signs, including pain, discomfort, and swelling, that occur during an acute episode. These applications are centered on the management of functional symptoms and the maintenance of vascular health.

“The primary goal of therapy is to manage functional symptoms and support patient comfort.”

Quick Fact: Relief for Heavy Legs

This section outlines the official eligibility and non-eligibility requirements for Флебодиа 600 (Diosmin 600 mg), strictly based on governmental regulatory documents.

---

Eligibility Scope

Classification	Population/Status
Allowed	Adults who do not have a contraindication.
Contraindicated	Individuals with known hypersensitivity or allergy to the active substance (Diosmin) or any of the product's excipients.
Use Not Recommended	Children and Adolescents (under 18 years) due to safety and efficacy not being established.
Use Not Recommended	Breastfeeding Mothers due to the absence of data on excretion into human milk.
Conditional Use	Pregnant Women; use is advised only if clearly necessary and under medical supervision due to insufficient human data.

---

Regulatory Summary

Regulatory documents establish the eligible user population as non-allergic adults. Use is absolutely contraindicated in patients with a history of hypersensitivity to Diosmin or its components. Furthermore, the medicine is not recommended for the pediatric and adolescent population (under 18 years) because its safety and effectiveness have not been confirmed in these age groups. For women who are pregnant or lactating, use is strongly restricted and generally not advised, reflecting an official position against use where data is limited or absent.

The interaction profile for Флебодиа 600 (Diosmin) is based on the formal regulatory assessment detailed in official prescribing information. This assessment specifically addresses the potential for drug–drug interactions, as well as interactions with food and other substances.

Official Interaction Status

Interaction Scope	Regulatory Statement
Drug–Drug Interactions	None documented.
Metabolic/Transporter Interactions	None documented.
Contraindicated Combinations	None documented.
Food, Alcohol, or Herbal Products	Not applicable / None documented.

The regulatory documentation, such as the Summary of Product Characteristics (SmPC) provided by national health authorities, establishes the official interaction status by defining the section on interactions as "Not applicable." This classification signifies that no clinically significant interaction patterns with other medicinal products have been formally reported or required for labeling since the medicine's market authorization.

Consequently, the official product labeling does not contain mandatory timing rules for co-administration, nor does it list specific medicinal products or substance classes that are restricted due to an interaction risk. This profile is consistent across all standard interaction categories, including pharmacokinetic and pharmacodynamic pathways, and extends to interactions with food, alcohol, and herbal supplements. The absence of documented interactions is the central element of the medicine's official interaction profile.

Modulating Venous Tone and Contractility

This mechanism focuses on the vascular smooth muscle within vein walls. The active component acts as a modulator, enhancing the effect of endogenous vasoconstrictors to increase venous tone and stiffen the vessel walls. This action increases the rate of venous return and modulates blood distribution, resulting from reduced venous compliance.

Protecting Microcirculation and Capillary Integrity

Флебодиа 600 acts on the microvascular endothelium to reduce its permeability. By inhibiting the release of certain inflammatory mediators and stabilizing the capillary barrier, the drug makes vessel walls less porous. This results in decreased extravasation of fluid into the interstitial space and lowered capillary filtration.

Anti-inflammatory and Endothelial Defense

The drug engages in local anti-inflammatory cascades by reducing leukocyte adhesion and neutralizing damaging free radicals and oxidative stress at the vessel lining. This mechanism reduces oxidative stress and limits the injury cascade on the vascular endothelium and wall structure.

Enhancing Lymphatic Drainage

Finally, the medication supports the body's natural fluid removal processes by enhancing the contractility and flow of the lymphatic vessels. This modulates lymphatic vessel contractility, contributing to enhanced lymph flow and greater removal of tissue fluid.

How to Use Флебодиа 600

Флебодиа 600 is a film-coated tablet containing 600 mg of Diosmin, intended solely for oral administration. The tablet must be swallowed whole with a glass of water, and its usage pattern—including dosage, frequency, and timing—is defined by the specific condition being addressed.

---

Administration Guidelines

Administration depends on whether the drug is used for chronic conditions or for an acute episode. The dosing regimen is established based on the clinical application of the medication.

Condition / Use Case	Standard Adult Dosing	Timing and Duration Constraint
Venous Insufficiency (Chronic)	One tablet (600 mg) daily.	Taken in the morning before breakfast. Long-term use is common, subject to regular reassessment.
Acute Hemorrhoids	Two to three tablets (1200–1800 mg) daily.	Taken during meals. Treatment should be of short duration (e.g., 7 days) and does not substitute for specific proctological treatment.

---

Administration Requirements and Restrictions

Dosage and frequency are adjusted based on the clinical scenario. The intensive, high-dose regimen for acute hemorrhoids is time-limited, while the single daily dose for chronic venous conditions is scheduled specifically to be taken pre-meal in the morning.

Use is restricted to the adult population. The safety and efficacy of Diosmin 600 mg have not been established for children and adolescents under 18 years of age. Furthermore, use is not recommended during pregnancy or lactation due to a lack of sufficient clinical data.

Research Evidence / Overview of Studies for Флебодиа 600

This overview describes the types of research that have been conducted on the active ingredient in Флебодиа 600 (Diosmin), focusing only on the available evidence and where uncertainty still exists. This is not medical advice or a guide to treatment.

---

Research Evidence for Chronic Venous and Lymphatic Insufficiency (CVI)

The core body of research for this condition involves short-term, randomized controlled trials (RCTs) and systematic reviews that explored how symptoms change over time in adults with Chronic Venous Disease (CVD). Researchers examined patient-reported outcomes describing discomfort, such as leg heaviness, leg pain, and cramps, and also monitored physical signs like changes in leg swelling (edema).

Studies monitored outcomes related to physical discomfort and reported patterns of change measured during the study period. Findings describe patterns observed in the studies, and research explored whether the use of this drug was associated with patterns of change in how patients reported their experience of pain and heaviness. Furthermore, studies reported on objective outcomes such as edema, which were observed in some trials over short-term follow-up intervals.

Comparative evidence remains insufficient for the single-ingredient Diosmin 600 mg dose against certain established treatment options for CVI. Long-term outcomes and the durability of any reported effects are not fully established by available RCTs, as follow-up durations were limited.

---

Research Evidence for Acute Hemorrhoidal Symptoms

Research for the management of hemorrhoidal symptoms involves short-term, randomized clinical trials applied in studies examining patient-reported experiences during periods of heightened symptom activity. The studies monitored outcomes describing episodic or acute changes, specifically focusing on physical discomfort and inflammatory states.

The findings from these trials describe patterns related to changes in acute symptoms and reported how symptoms evolved in the observed populations during the study period. It is important to note that a significant portion of the literature used a combination product (Diosmin and another flavonoid), meaning the evidence for the single-ingredient 600 mg dose requires careful context. Long-term effects on recurrence are not fully established, as trials were typically very short in duration (days to weeks).

---

Study Quality, Limitations, and Research Gaps

Evidence quality varies across studies, and some trials suffer from modest sample sizes. A key limitation is the heterogeneity in the literature, which combines studies of the single-ingredient Diosmin 600 mg with those of a different, two-ingredient flavonoid product. The inclusion of differing formulations means that drawing conclusions solely about the single-ingredient drug is limited by the research base's structure. Furthermore, data are still emerging regarding comparative evidence against non-pharmacological therapies, and research provides context but not individual predictions.

Key Studies & References WHO ATC Classification System: Diosmin (C05CA03)

Common questions about Флебодиа 600 (FAQ)

---

Q: When is the best time of day to take the tablet for chronic venous insufficiency?

Official administration guidelines state that the tablet for chronic venous insufficiency is intended to be taken in the morning before breakfast. This specific timing is noted in the regulatory prescribing information.

---

Q: What should I do if I experience stomach pain while taking Флебодиа 600?

Stomach pain, or gastralgia, is listed in regulatory documents as a common adverse reaction. Official information indicates that minor gastrointestinal disturbances are generally mild and rarely require discontinuation of treatment. The full assessment of persistent or severe pain is a matter for a healthcare professional.

---

Q: Is Флебодиа 600 an anti-inflammatory drug?

While the medicine is categorized as a phlebotropic agent, its mechanism of action is described as engaging in local anti-inflammatory cascades. This involves processes such as reducing the adhesion of white blood cells (leukocytes) and neutralizing free radicals at the vessel lining.

---

Q: What is the maximum duration I can take this for acute hemorrhoids?

The regulatory documents state that use for an acute hemorrhoidal crisis is limited to short-term administration only. For example, official guidelines indicate a duration of around 7 days.

---

Q: Is it okay to crush or chew the tablet to make it easier to swallow?

No. The official product instructions state that this medicine is a film-coated tablet designed solely for oral administration and must be swallowed whole with water. Product information states that the tablet should not be crushed or chewed.

---

Q: Can I take Флебодиа 600 with blood thinners like warfarin?

According to official product labeling, no clinically significant drug-drug interactions are documented for Флебодиа 600. The interaction section is generally classified as 'Not applicable,' meaning no mandatory timing rules or restrictions with other medicinal products have been formally reported.

How to Store and Dispose of Флебодиа 600

The official regulatory labeling for this medicine outlines mandatory conditions to preserve the product's quality and ensure safe disposal.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30 C.
Protection	Keep the medicine protected from light and moisture.
Container	Maintain the tablets in the original container/package until use.
Safety	Must be stored out of the sight and reach of children.

The stated shelf life is valid only when the product is kept under these required environmental and temperature controls.

Disposal Instructions

Unused or expired Флебодиа 600 must be handled as pharmaceutical waste. Do not dispose of the tablets via wastewater or with household garbage. Discard the product by following the specific collection and disposal instructions established by local regulatory authorities.